NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Zentalis reported its financial results for the fourth quarter and full year 2022, highlighting progress in its clinical programs and financial position.
Zentalis Pharmaceuticals reported a cash balance of $437.4 million as of December 31, 2022, projecting a cash runway into Q2 2025. The company is focused on advancing its clinical development strategy for azenosertib and ZN-d5.
- On track to declare monotherapy RP2D for azenosertib in 1H 2023.
- Pursuing Cyclin E1 as a patient enrichment strategy for azenosertib monotherapy in ovarian cancer.
- Initiated enrollment in Phase 1/2 azenosertib + BEACON regimen combination study in BRAF V600E mutated mCRC.
- Enrollment ongoing in clinical trials investigating ZN-d5 in (AL) amyloidosis.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$0
Forward guidance
Zentalis is focused on several key milestones in 2023, including declaring the RP2D for azenosertib, advancing the Cyclin E1 enrichment strategy, presenting clinical data for ZN-d5, and continuing enrollment in ongoing clinical trials.
Tailwinds
- Declaring a monotherapy RP2D for azenosertib in the first half of 2023.
- Presenting Cyclin E1 preclinical data in the first half of 2023.
- Reporting results from the Phase 1b chemotherapy combination clinical trial in ovarian cancer in the second half of 2023.
- Announcing interim clinical data and declare the RP2D for the Phase 1/2 monotherapy clinical trial of ZN-d5 in relapsed or refractory light chain (AL) amyloidosis in the second half of 2023.
- Providing preliminary data from the Phase 1/2 combination study of ZN-d5 and azenosertib in AML in the second half of 2023.
Headwinds
- Limited operating history may make it difficult to evaluate the business and predict future success.
- The company has and expects to continue to incur significant losses.
- The company needs additional funding, which may not be available.
- Substantial dependence on the success of lead product candidates.
- Potential unforeseen events during clinical trials could cause delays or other adverse consequences.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-1.7%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+2.4%
Avg return
30 days after
58%
14 / 24 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -1.7% | — | |
| Q4 2025 | +3.1% | -3.7% | +49.1% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro